Nutriband (id:5942 NTRB)
4.81 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 1:23:39 PM)
Exchange closed, opens in 1 day 20 hours
-3.68 USD (-3.68%)
1.91 USD (1.91%)
-40.76 USD (-40.76%)
-6.24 USD (-6.24%)
87.52 USD (87.52%)
-66.99 USD (-66.99%)
-31.58 USD (-31.58%)
About Nutriband
Market Capitalization 52.49M
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
| Headquarters (address) |
121 South Orange Avenue Orlando 32801 FL United States |
| Phone | 407 377 6695 |
| Website | https://www.nutriband.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | NTRB |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.22 - 9.60 |
| Market Capitalization | 52.49M |
| P/E trailing | -6.97 |
| P/E forward | -20.57 |
| Price/Sale | 26.02 |
| Price/Book | 6.51 |
| Beta | 0.416 |
| EPS | -0.810 |
| EPS United States (ID:6, base:3400) | 24.26 |